

# HTRS



**HEMOSTASIS  
& THROMBOSIS**  
RESEARCH SOCIETY

**Supported by a medical educational  
grant from Takeda**



## **HTRS 2022 Mentored Research Award Recipient**



### **Diego Adrianzen Herrera, MD**

**Assistant Professor, Division of Hematology and Oncology  
Larner College of Medicine at The University of Vermont**

**Mentors: Neil A. Zakai, MD MSc | Aditi Shastri, MD | Pamela Lutsey, PhD MPH**

**Project Title: “Identifying Patient and Treatment Factors Associated with  
Cardiovascular Disease Risk and Mortality in Myelodysplastic Syndromes”**

Dr. Adrianzen Herrera is a clinician and clinical investigator with a focus on health outcomes research. He obtained his medical degree in Peru and moved to New York City to complete his residency at Mount Sinai Morningside West - Icahn School of Medicine and his fellowship at Montefiore Medical Center - Albert Einstein College of Medicine. He is board certified in Internal Medicine, Hematology and Medical Oncology, and is currently pursuing a MSc Degree in Clinical and Translational Research at UVM's Graduate College. As a fellow, Dr. Adrianzen-Herrera conducted a study which identified myelodysplastic syndromes (MDS) as an independent risk factor for cardiovascular disease. His current research focus is on the prevention and targeting of arterial thrombosis and cardiovascular health as a mechanism to improve outcomes in patients with MDS. His MRA project has granted him participation in the American Society of Hematology's Clinical Research Training Institute (CRTI); he aims to investigate clinical risk factors and the effect of MDS characteristics and therapies on arterial thrombosis and cardiovascular outcomes among MDS patients in the SEER-Medicare database. His goal is to decrease cardiovascular morbidity and mortality in MDS by building risk models aimed at targeting cardiovascular health from initial MDS diagnosis.